P Pharming Group NV
P
Ouvert
1.151 -0.09
Résumé
Variation du prix de l'action
24h
Min
1.135
Max
1.156
Revenu | -10M -5.1M |
|---|---|
Ventes | -36M 71M |
P/E Moyenne du Secteur | 56.75 50.958 |
BPA | -0.006 |
Marge bénéficiaire | -7.196 |
Employés | 407 |
EBITDA | -4.8M -2.1M |
Prochains Résultats | 30 juil. 2026 |
|---|
Capitalisation Boursière | -207M 802M |
|---|---|
Ouverture précédente | 1.24 |
Clôture précédente | 1.151 |
Pharming Group NV Graphique
Les performances passées ne sont pas un indicateur fiable des résultats futurs.
À Propos Pharming Group NV
Pharming Group N.V., a biopharmaceutical company, develops and commercializes protein replacement therapies and precision medicines for the treatment of rare diseases in the United States, Europe, and internationally. The company offers RUCONEST, a recombinant C1 esterase inhibitor for the treatment of acute attacks in adult and adolescent patients with acute hereditary angioedema (HAE); and Joenja (leniolisib), an oral small molecule PI3K" inhibitor for the treatment of activated phosphoinositide 3-kinase delta syndrome. It also develops OTL-105, an investigational ex-vivo autologous hematopoietic stem cell gene therapy for the treatment of HAE. The company has a development collaboration and license agreement with Novartis; and a strategic collaboration agreement with Orchard Therapeutics plc for research, development, manufacturing, and commercialization of OTL-105. Pharming Group N.V. was incorporated in 1988 and is headquartered in Leiden, the Netherlands.
